SARS-CoV-2 Virus Vaccines
Moderna
On Monday Moderna (MRNA) started its Phase 3 clinical trial on 30,000 people with its product mRNA-1273.
Separately, in a press release Moderna announced a preclinical study evaluating its product mRNA-1273 has been published in The New England Journal of Medicine. This study . . .
This content is for paid subscribers.
Impacting News
July 29, 2020
